Researchers at Rutgers University have identified a potential association between glucagon-like peptide-1 receptor agonists and reduced violent behaviour in individuals with impulsive personality traits. The observational analysis examined adults with documented histories of impulsivity and aggression, finding that those using GLP-1 medications—commonly prescribed for diabetes and weight management—showed a substantially weakened connection between impulsive tendencies and violent outcomes.
While the finding cannot establish causation, the neurobiological mechanisms underlying GLP-1 action offer a plausible hypothesis. These drugs are known to act on multiple brain regions governing impulse control, reward processing, and emotional regulation, including the prefrontal cortex and amygdala. However, researchers emphasize that the observational nature of this study precludes therapeutic claims, and randomised controlled trials are essential before considering any off-label applications. The work adds to growing interest in how metabolic medications may influence neuropsychiatric outcomes.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Announcement
📰 Read the full article: GLP-1 Drugs Linked to Lower Violent Behaviour in Rutgers Study →
